Autres langues ProPhase Labs, Inc.

Actions

PRPH

US74345W1080

Temps Différé Nasdaq Autres places de cotation 18:26:39 13/05/2024			Varia. 5j.	Varia. 1 janv.
5,115 ^USD	+1,29%		-3,21%	+14,35%

09/05	Transcript : ProPhase Labs, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	ProPhase Labs, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Earnings Flash (PRPH) PROPHASE LABS Posts Q1 Revenue $3.6M, vs. Street Est of $9.9M	09/05
Earnings Flash (PRPH) PROPHASE LABS Posts Q1 Revenue $3.6M	09/05
ProPhase Labs : Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test - Form 8-K	09/05
ProPhase Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.	09/05
PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9	02/05
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	25/04
Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup	16/04
ProPhase Labs Unveils Project ZenQ-AI	16/04
ProPhase Labs, Inc. Unveils Project ZenQ-AI	16/04
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024	10/04
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/04
MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq	18/03
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives	15/03
ProPhase Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
North American Morning Briefing : Inflation -2-	15/03
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024	08/03
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART	20/02
Prophase Labs, Inc. Announces Important Developments in the Company?s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test	20/02
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ProPhase Labs, Inc.

Actions

PRPH

US74345W1080

Autres langues

Filtres